LH-RH receptor antagonists
US6136781A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jun 6, 1996 |
| Grant date | Oct 24, 2000 |
| Priority date | — |
| Expiry date | Jun 6, 2016 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S424/814
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The LH-RH receptor antagonists containing cyclic pentapeptides or salts thereof and novel cyclic pentapeptide or salts thereof are provided. The LH-RH receptor antagonists of the present invention are effective as medicines for preventing and curing sex hormone-dependent cancers (e.g., prostatic cancer, uterine cancer, mammary cancer, pituitary tumor, etc.), prostatomegaly, endometriosis, hysteromyoma, puberty precox, amenorrheal syndromes, multilocular ovarian syndromes, comedo, etc. and are also effective as pregnancy controlling agents (e.g., contraceptives, etc.) and menstrual cycle controlling agents. Moreover, these are also useful in the livestock industry for the control of the estrus of animals and also for the improvement in the quality of meat and for the control of the growth of animals, as well as in the marine products industry as spawning promoters for fishes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.